<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04807686</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02448-47</org_study_id>
    <nct_id>NCT04807686</nct_id>
  </id_info>
  <brief_title>Attenuation of Tonal Tinnitus by Lateral Inhibition Therapy</brief_title>
  <acronym>TIL</acronym>
  <official_title>Attenuation of Tonal Tinnitus by Lateral Inhibition Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ramsay Générale de Santé</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dr Quemar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ramsay Générale de Santé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lateral Inhibition Therapy (TIL) corrects the patient's hearing by notched amplification on&#xD;
      the patient's listening soundtrack. This half-octave notch is targeted at tinnitus&#xD;
      frequencies measured tonal. The device slightly increases the amplification around the notch,&#xD;
      so that the cerebral cortex compensates for this &quot;gap&quot; in the sound spectrum, masking the&#xD;
      crippling tinnitus at the same time. This research is based on a new algorithm developed by&#xD;
      the SIEMENS Company which proposes an attenuation of tonal tinnitus by a TIL by notched&#xD;
      amplification emitted by the hearing device, object of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In France, up to 16 million people suffer from tinnitus or ringing in the ears daily. This&#xD;
      parasitic sound that does not come from the patient's environment can interfere with each&#xD;
      individual in a variable way, sometimes creating an insurmountable handicap which has not&#xD;
      known any effective treatment validated to date.&#xD;
&#xD;
      Lateral Inhibition Therapy (TIL) corrects the patient's hearing by notched amplification on&#xD;
      the patient's listening soundtrack. This half-octave notch is targeted at tinnitus&#xD;
      frequencies measured tonal. The device slightly increases the amplification around the notch,&#xD;
      so that the cerebral cortex compensates for this &quot;gap&quot; in the sound spectrum, masking the&#xD;
      crippling tinnitus at the same time. This research is based on a new algorithm developed by&#xD;
      the SIEMENS Company which proposes an attenuation of tonal tinnitus by a TIL by notched&#xD;
      amplification emitted by the hearing device, object of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tinnitus Handicap Inventory</measure>
    <time_frame>2 months</time_frame>
    <description>The primary endpoint is the score (out of 100 points) obtained on the Tinnitus Handicap Inventory (THI), expressed in terms of variation from the baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>traditional algorithm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>notched-type algorithm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Auditory simulation</intervention_name>
    <description>Each patient will be delivered each of the 2 auditory stimulation protocols considered in the context of the research: stimulation with a traditional algorithm called AT and stimulation with a notched-type algorithm called AE. The order in which will be carried out, for the same patient, each of these 2 protocols (AT then AE or AE then AT) will be randomized.</description>
    <arm_group_label>notched-type algorithm</arm_group_label>
    <arm_group_label>traditional algorithm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old.&#xD;
&#xD;
          -  Patient with disabling tonal tinnitus (THI score&gt; 40) for more than 6 months.&#xD;
&#xD;
          -  Patient with a hearing loss of at least 25dB, centered on the frequency of tinnitus&#xD;
             and requiring hearing aids&#xD;
&#xD;
          -  Patient who has never used a hearing aid or a tinnitus masking system.&#xD;
&#xD;
          -  Patient who stopped all tinnitus treatment at least 1 month before the start of the&#xD;
             study (drug treatment, psychotherapy).&#xD;
&#xD;
          -  Patient being willing to attend all of the visits planned as part of the study.&#xD;
&#xD;
          -  Patient affiliated or beneficiary of a social security scheme.&#xD;
&#xD;
          -  Patient having signed the free and informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor patient.&#xD;
&#xD;
          -  Patient with hyperacusis&#xD;
&#xD;
          -  Patient already with a hearing aid or tinnitus masker.&#xD;
&#xD;
          -  Patient undergoing psychotropic or neurotropic drug treatments.&#xD;
&#xD;
          -  Patient with a history of psychological or psychiatric disorders.&#xD;
&#xD;
          -  Patient with a contraindication to wearing hearing aids.&#xD;
&#xD;
          -  Patient suffering from non-disabling tinnitus (THI score &lt;40).&#xD;
&#xD;
          -  Patient suffering from intermittent, non-tonal or pulsatile tinnitus.&#xD;
&#xD;
          -  Patient participating in another clinical study.&#xD;
&#xD;
          -  Protected patients: adults under guardianship, curatorship or other legal protection,&#xD;
             deprived of their liberty by judicial or administrative decision.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne Quemar, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ramsay santé</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JF OUDET</last_name>
    <phone>+33683346567</phone>
    <email>jf.oudet@ecten.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>MH Barba</last_name>
    <phone>+ 336 64 88 87 04</phone>
    <email>mh.barba@ecten.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Privé Clairval</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Quemar</last_name>
      <phone>334 91 17 17 22</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

